Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RARE Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: February 20, 2026
Report Source: 2025 Annual Report
Ultragenyx Pharmaceutical Inc. Stock Analysis RARE
United States Health Care Mid Cap Report: Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Read More Ultragenyx Pharmaceutical Inc (RARE) Chart
Key Statistics of Ultragenyx Pharmaceutical Inc (RARE)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$28.58Volume
2.04MP/E Ratio (TTM)
-52 Week Range
Market Cap
2.34BAvg. Volume
1.89MDividend Yield
-Financial Metrics & Statements of Ultragenyx Pharmaceutical Inc (RARE)
FAQ's for Ultragenyx Pharmaceutical Inc (RARE)
- According to Musaffa’s Shariah screening methodology, Ultragenyx Pharmaceutical Inc (RARE) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ultragenyx Pharmaceutical Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Ultragenyx Pharmaceutical Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Ultragenyx Pharmaceutical Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Ultragenyx Pharmaceutical Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Ultragenyx Pharmaceutical Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.